Skip to content
Saturday 8 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

pharmaceuticals

  • Meet the founder searching for the ‘holy grail’ of cancer treatment

    October 8, 2024

    Jennifer Sieg speaks with Hilmar Warenius about how his discovery of a new type of cancer treatment could be well on its way to revolutionising the pharmaceutical industry

  • Astrazeneca boosts cardiovascular pipeline with licensing deal

    October 7, 2024

    Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]

  • Vet service Animalcare reports positive results after balance sheet “transformation”

    September 24, 2024

    International veterinary pharmaceutical and services business Animalcare has reported a “transformation” in its balance sheet after two sales worth £27.7m, as well as a boost in revenue. The AIM-listed, York-based company told markets this morning that its revenue rose by five per cent to £36.9m, from £35.2m in the first half of 2023. Underlying earnings [...]

  • AMS Group reports ‘strong’ first half amid rumoured takeover interest

    September 18, 2024

    In the six months to June, revenue rose by eight per cent to £68.0m, with strong growth in the firm's surgical business unit offsetting "challenges" in its Woundcare unit.

  • Astrazeneca drags down the FTSE 100 following mixed cancer trial results

    September 10, 2024

    Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.

  • Fusion Antibodies: Pharma firm has ‘challenging’ year despite strong sales pipeline

    September 5, 2024

    Pharmaceutical company Fusion Antibodies said it had a “challenging” year but has seen its sales pipeline grow. Fusion posted audited revenue of £1.14m for the year ended March 2024, a 60 per cent drop from the £2.9m it reported in 2023. The company, which specialises in antibody discovery, engineering and supply for therapeutic drugs, said [...]

  • Private equity groups circle UK pharmacy wholesaler

    September 2, 2024

    HIG and Capvest have joined a line of private equity groups looking to buy the largest supplier of goods to British pharmacies, AAH Pharmaceuticals, from German private equity firm Aurelius. AAH has been put up for sale again only a few years after being bought by Aurelius in 2022, according to the Financial Times. The [...]

  • Curing cancer and cleaning our oceans? Here’s why I’m betting on biotech

    September 1, 2024

    Something that can cure cancer and clean our oceans? Biotech sounds too good to be true, but some things really are just like magic, writes Andrew Craig.

  • AS Watson: Pharma partner Icanthera’s cash reserves soar

    August 27, 2024

    UK-based pharmaceutical company Icanthera said its cash reserves soared over the last year as it has struck a major deal and is focusing on developing new products. The company that manufactures dermatology and oncology treatments said its cash position increased to £61,000 at 31 March 2024, up from £3,000 in the previous year. Icanthera said [...]

  • GSK receives US breakthrough therapy designation for lung cancer treatment

    August 20, 2024

    Pharmaceutical group GSK has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for a key lung cancer treatment. The breakthrough therapy designation is designed to expedite the development and review of drugs with the potential to treat a serious condition. Only treatments that are shown to offer a substantial improvement [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • …
  • Page 20
  • Next

Trending Articles

  • Why HMRC is huge Premier League transfer window tax headache

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Thunder Call set to Strike in Shergar Cup Sprint

  • Moore can set Ozat on Road to victory at Shergar Cup

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook